RE:Is this new?wofats wrote: Some sort of deal on this?
from Sedar
NOVARTIS PHARMA AG,
Wofats ... it's the asset purchase agreement with Novartis (for Excelon).
On April 23, 2021 Knight announced that it has entered into a definitive agreement under which Knight will acquire the exclusive rights to manufacture, market and sell Exelon® (rivastigmine Patch, Capsules and Solution) in Canada and Latin America (the “Territory”), as well as an exclusive license to use the intellectual property and the Exelon trademark, from Novartis within the Territory. Exelon (rivastigmine) is a prescription product that was first approved in 1997 and is currently registered and sold in approximately 90 countries. Exelon is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer’s disease.